Leerink analyst Paul Matteis says that despite last night's Phase 2 failure, Neurocrine Biosciences' Ingrezza in pediatric Tourette syndrome program "is not dead." The mechanistic rationale for valbenazine in Tourette's is still strong, Matteis tells investors in a research note. He thinks there was about $3-$4 for pediatrics priced into the stock. The analyst maintains 30% odds of success for valbenazine in Tourette's, but pushed sales out two years to 2022. He lowered his price target for Neurocrine shares to $66 from $68 and reiterates an Outperform rating on the name.